Any content you receive is for information purposes only. Always conduct your own research.
*Sponsored
Intelligent Bio Solutions Inc. (Nasdaq: INBS) Just Landed On Our Watchlist This Morning—Tuesday, September 1, 2026…
Don’t Miss Our Next Update—Get Real-Time Alerts Sent Directly To Your Phone. Up To 10X Faster Than Email. Take A Look At (INBS) While It’s Still Early… September 1, 2026 Dear Reader, With less than 90 minutes until the opening bell, (Nasdaq: INBS) is back on the radar after a string of developments that make its fingerprint-based screening platform difficult to ignore. The biggest names in dr-ug screening have been doing things the same way for decades. Urine cups. Oral swabs. Lab queues. Chain-of-custody paperwork that can stretch resolution timelines from hours into days. These methods work. But they're slow, they're invasive, and in a world that increasingly demands speed and portability in every other category of field testing, the standard approach to workplace dr-ug screening has barely moved since the 1990s. Think about that for a moment. We've reinvented how we screen for disease, how we monitor blood sugar, how we test for pathogens — but the way a construction foreman confirms that a crane operator is fit for duty still involves a trip to a clinic and a plastic cup. Which is exactly why Intelligent Bio Solutions Inc. (Nasdaq: INBS) deserves a closer look right now. This medtech company has built something fundamentally different… a portable screening system that collects samples from fingerprint sweat in seconds and delivers results in under ten minutes. No needles. No cups. No lab wait times. No specialized technicians required. And the timing could not be more compelling. The global dr-ug screening sector is valued at roughly $8.29B in 2026 and projected to reach approximately $25.3B by 2036, according to ResearchAndMarkets — reflecting an 11.8% compound annual growth rate. North America leads the sector, driven by tightening compliance mandates, expanded workplace safety regulations, and growing adoption of rapid on-site testing. That's the backdrop. Now here's what makes (INBS) stand out in that context. Intelligent Bio Solutions Inc. (Nasdaq: INBS) is topping our watchlist this morning—Tuesday, September 1, 2026. 
(Nasdaq: INBS) has a float less than 3M listed as available to the public—with a float that small, the potential exists for big moves if demand begins to shift. In August alone, INBS made an approx. 102% move from around $1.72 on 8/04/2026 to $3.49 on 8/17/2026, according to Barchart. What a Fingerprint Can Reveal
The core technology is the Intelligent Fingerprinting Dr-ug Screening System. It uses fingerprint sweat analysis — a proprietary, non-invasive method — to screen for recent use of opiates, cocaine, methamphetamine, and cannabis. The system collects sweat samples directly from a donor's fingertip, analyzes them through a reader device, and returns results at the point of collection. Sample collection takes seconds. Results arrive in under ten minutes. The entire workflow is designed for the field — job sites, transport depots, distribution centers, mining operations — places where traditional lab-based testing creates logistical headaches and operational delays. And the company's usability study, completed in August 2026, confirmed that operators with no specialist background could be trained to administer the system effectively. Fifteen operators participated, and the outcome reinforced that this is a tool built for workplace safety personnel — not laboratory technicians. Peter Passaris, Vice President of Product Development, noted that the simpler and more reliable the screening process, the stronger the company's position in the market. That's the kind of advantage that compounds over time… Intelligent Bio Solutions Inc. (Nasdaq: INBS) already serves 502 active customers across the UK, Europe, APAC, and the Middle East. Its reader installed base has grown 22% year-over-year to 1,886 units, with each reader placement creating recurring demand for consumable cartridges — the foundation of the company's razor-razorblade revenue model. The company also recently strengthened its European IP portfolio with its eighth patent grant, further protecting its proprietary fingerprint-based screening technology. Closing in on the FDA
Here is where the story gets particularly worth watching… Intelligent Bio Solutions Inc. (INBS) is in the final stages of assembling its FDA 510(k) submission package — the regulatory gateway to the U.S. dr-ug screening market, the largest on earth. Throughout fiscal 2026 and into early fiscal 2027, the company executed a structured, multi-study clinical program designed to address every dimension the FDA evaluates: safety, accuracy, usability, specificity, security, and precision. The depth of that program is worth understanding, because each study adds a layer of evidence to the submission package. Precision testing confirmed reproducibility across more than 1,600 tests, three production runs, and three independent sites — demonstrating that the system delivers consistent results regardless of where or how it's manufactured and operated. An interference study evaluated whether everyday contaminants — hand creams, oils, dirt, water — affect the system's accuracy under real-world conditions. This is the kind of field-readiness testing that separates a lab concept from a deployable tool. A method comparison study enrolled 135 participants across three independent U.S. clinical sites over three weeks, measuring sensitivity, specificity, and accuracy in occupational screening environments. All specimens are being independently verified via LC-MS/MS analysis. Independent third-party penetration testing identified no major cybersecurity vulnerabilities — and all review items have since been resolved, with 100% of medium-risk items remediated and all 19 software bill of materials vulnerabilities fully cleared. And the company recently recertified under ISO 13485:2016, the internationally recognized quality management standard for medical device manufacturers — which now aligns with the FDA's newly amended Quality Management System Regulation. All clinical data collection across the company's FDA 510(k) clinical study program is now complete. The 510(k) submission is on track for the second half of calendar 2026… That submission targets codeine detection as the initial indication — and clearance could open the door to U.S. market entry beyond current Forensic Use Only settings, spanning workplace testing, criminal justice, pain management, law enforcement, and substance abuse treatment. The significance of that clearance is hard to overstate. Right now, the Intelligent Fingerprinting system is commercially deployed outside the U.S. across workplace, law enforcement, and government settings. FDA clearance would give the company access to the single largest dr-ug screening market in the world — one where federal mandates, corporate compliance programs, and a growing substance abuse concern are all pushing demand in the same direction. Already Building Revenue
While the FDA pathway is the headline, the numbers underneath tell a compelling story on their own. Intelligent Bio Solutions Inc. (INBS) just reported its fiscal 2026 full-year results — and the trajectory is clear. Total revenue reached $4.2M, a 38% increase year-over-year. Gross margin expanded to 48.63%… up 778 basis points from the prior year. That margin expansion reflected a strategic combination: the transition to Syrma Johari as a high-quality, lower-cost manufacturing partner — expected to deliver annual production cost savings of more than 40% and an expected gross margin improvement of approximately 20 percentage points — along with an optimized product mix weighted toward higher-margin consumable cartridges. Consumable cartridge output reached 106,500 units, a 35% increase that outpaced the rate of installed base growth and confirmed deepening utilization among existing customers. That dynamic is worth pausing on… When cartridge consumption grows faster than the reader base, it signals that customers who already have the hardware are using it more. That's recurring revenue accelerating — exactly the pattern a razor-razorblade model is built to generate. The company also secured a partnership with Bouygues UK, part of global construction group Bouygues Construction, for a dr-ug-testing rollout across a high-profile, safety-critical construction environment — exactly the kind of customer that validates the system's field readiness at scale. And there's another detail worth noting… The company is validating a rapid screening cartridge targeting 70% faster results — which could further differentiate the system in field environments where speed matters most. Harry Simeonidis, President and CEO, said it well: "We are now firmly in the final stretch of data analysis and assembly of our FDA 510(k) submission package, and we remain focused on bringing our technology to the U.S. market." 7 Reasons Why We're Watching (INBS) This Morning…
1. Small-Float: According to Yahoo Finance, less than 3M shares exist in the public float, the potential exists for big moves if demand begins to shift. 2. 38% Revenue Growth: Fiscal 2026 full-year revenue reached $4.2M, a 38% year-over-year increase driven by a 22% expansion in the reader installed base and a 35% jump in consumable cartridges, per the company's latest results. 3. FDA 510(k) Approaching: All clinical data collection across the company's FDA 510(k) study program is complete, with submission targeting H2 2026 for codeine detection clearance and planned U.S. market entry. 4. Reproducibility Confirmed Across 1,600+ Tests: Precision testing confirmed consistent, reliable results across more than 1,600 tests, three production runs, and three independent sites — adding depth to the submission package. 5. Expanding Gross Margin: Gross margin expanded to 48.63%, up 778 basis points year-over-year, reflecting the transition to Syrma Johari as a manufacturing partner expected to deliver 40%+ production cost savings and approximately 20 percentage points of annual gross margin improvement. 6. ISO 13485:2016 Recertification: The company recertified to the internationally recognized quality management standard for medical device manufacturers, aligning with the FDA's newly amended Quality Management System Regulation. 7. Bouygues UK Partnership: A strategic partnership with Bouygues UK, part of global construction group Bouygues Construction, adds a significant new customer in a high-profile, safety-critical environment. Take A Look At (INBS) While It’s Still Early…
There's a version of this story where a company builds a novel, non-invasive screening technology… proves it works across more than half a dozen clinical and technical studies… scales it commercially to 502 active customers and $4.2M in annual revenue with expanding margins… and then unlocks the largest dr-ug screening market on earth with a single regulatory clearance. That version may already be underway with Intelligent Bio Solutions Inc. (Nasdaq: INBS). Which is why (INBS) is at the top of our watchlist this morning, Tuesday, September 1, 2026. Sincerely, Jeff Ackerman
Managing Editor
Stock News Trends |
No comments:
Post a Comment